Proprietary technologies can create significant network restrictions in cancer research. For example, some biotech companies may develop innovative diagnostic tools or treatment methods but restrict access to these technologies via patents or exclusive licenses. This can limit the ability of other researchers to validate findings or develop complementary approaches.
